Lactobacillus reuteri Protectis shown to reduce colic in infants

A double-blind, placebo-controlled study of 80 colicky infants showed that
the crying time was significantly reduced among the infants supplemented by
drops with the probiotic Lactobacillus reuteri
Protectis compared to those in the placebo group. The quality of life for the
parents and families were also significantly improved in the probiotic group
compared to the placebo group.

The study was done by
Hania Szajewska who is Professor and Chair of the Department of Paediatrics at
the Medical University of Warsaw in Poland. She is one of the most well reputed
experts in probiotics in the world and has conducted numerous clinical trials.

The significant reduction in crying time confirm earlier studies with Lactobacillus reuteri Protectis
in infants with colic, but further, and for the first time, the parents
perception of the baby’s colic and the quality of life of the parents and the
family have been measured. These parameters showed highly significant
improvements in the probiotic group as compared to the placebo group. The new
study also included colic diagnosed infants that were partially fed with
formula, extending the findings of earlier studies, which were performed in
exclusively breast-fed infants.

The study was performed according to the highest standards of clinical
trial reporting (CONSORT). It was published in The Journal of Pediatrics on 14 September 2012.

“This is the third independent study with Lactobacillus reuteri Protectis in infants
and the effectiveness of our product in reducing symptoms of colic is now very
clear. This new and strong data further strengthens the position of Lactobacillus reuteri
Protectis within the paediatric field”, says Peter Rothschild, President,
BioGaia.

Colic a common and frustrating problem

Colic refers to a clinical condition of inconsolable crying, fussing and
irritability, most often in the evenings, in an otherwise healthy baby during
the first four months of life, typically peaking at approximately six weeks of
life. According to the diagnostic criteria, a child has infant colic if it has
unexplained episodes of fussing and crying for at least three hours a day for
three days a week or more for at least one week. Up to 26% of infants are
diagnosed with colic, making the condition one of the most frequent reasons for
visits to paediatricians, family practitioners and community nurses.

Lactobacillus reuteri – a well
researched probiotic

Lactobacillus reuteri is one of the
world’s most well researched probiotics, especially in young children. To date
92 clinical studies using BioGaia’s human strains of Lactobacillus reuteri have
been performed in more than 7,700 individuals of all ages. Half of the studies
have been performed in premature babies, infants and children. Results are
published in 62 articles in scientific journals (September 2012).

Latest press releases from BioGaia

2012-09-07 BioGaia’s probiotic prevented necrotizing
enterocolitis in high risk premature infants

2012-08-21 BioGaia AB Interim report 1 January-30 June
2012

2012-06-13 BioGaia signs exclusive agreement for its
probiotic drops and oral rehydration with Nestlé’s Gerber division in the
United States

BioGaia has published this information in accordance with
the Swedish Securities Market Act. The information was issued for publication
on 17 September 2012, 15:30 am CET.

For additional information please contact

Peter Rothschild, President, telephone: +46 8 555 293 00

Eamonn Connolly, Senior Vice President Research, BioGaia, telephone: +46 8 555
293 00

BioGaia is a healthcare
company that develops, markets and sells probiotic products with
documented health benefits. The products are primarily based on the lactic
acid bacterium Lactobacillus
reuteri
, which has probiotic, health-enhancing effects. The
class B share of the Parent Company BioGaia AB is quoted on the Mid Cap
list of the NASDAQ OMX Nordic Exchange Stockholm.